Results 11 to 20 of about 3,307,905 (304)

Structural basis for potent neutralization of SARS-CoV-2 and role of antibody affinity maturation

Nature Communications, 2020
Currently there is neither a vaccine nor an effective treatment strategy available for COVID19. Here, Hurlburt et al. provide the crystal structure of a patient-derived monoclonal antibody neutralizing SARS-CoV-2 via shedding of the S1 subunit and ...
Nicholas K. Hurlburt, Emilie Seydoux, Yu-Hsin Wan, Venkata Viswanadh Edara, Andrew B. Stuart, Junli Feng, Mehul S. Suthar, Andrew T. McGuire, Leonidas Stamatatos, Marie Pancera   +9 more
doaj   +1 more source

The Changing Landscape of Therapeutic Cancer Vaccines-Novel Platforms and Neoantigen Identification.

, 2021
Therapeutic cancer vaccines, an exciting development in cancer immunotherapy, share the goal of creating and amplifying tumor-specific T-cell responses, but significant obstacles still remain to their success.
Harrington, KJ, Ehrnrooth, E, Cohen, EEW, Jou, J, Zocca, M-B   +4 more
core   +1 more source

Targeting tumor heterogeneity with neoantigen-based cancer vaccines

, 2023
Neoantigen-based cancer vaccines have emerged as a promising immunotherapeutic approach to treat cancer. Nevertheless, the high degree of heterogeneity in tumors poses a significant hurdle for developing a vaccine that targets the therapeutically ...
Chen, Shuxiong, Ma, Linlin, Pounraj, Saranya, Mazzieri, Roberta, Rehm, Bernd HA, Dolcetti, Riccardo   +5 more
core   +1 more source

Cancer vaccines [PDF]

Trends in Pharmacological Sciences, 1993
1993 represents the 100th anniversary of William Coley's first report of tumor regressions induced by immune system activation in response to bacterial toxins. While many subsequent cancer vaccine trials have yielded tantalizing results, active immunotherapy has not yet become an established modality of cancer therapy.
openaire   +4 more sources

Guidance for peptide vaccines for the treatment of cancer [PDF]

, 2014
Recent progress in fundamental understanding of tumor immunology has opened a new avenue of cancer vaccines. Currently, the development of new cancer vaccines is a global topic and has attracted attention as one of the most important issues in Japan ...
Junji Furuse, Yasuo Ohashi, Yamaue, Hiroki, Atsushi Otsu, Kazuto Nishio, Furuse, Junji, Hironobu Minami, Nakamura, Yusuke, Yoshiyuki Yamaguchi, Hiroyuki Suzuki, Tsunoda, Takuya, Yusuke Nakamura, Suzuki, Hiroyuki, Shimazawa, Rumiko, Hayashi, Yuzo, Takuji Okusaka, Ohashi, Yasuo, Okuno, Kiyotaka, Nishio, Kazuto, Rumiko Shimazawa, Otsu, Atsushi, Yuzo Hayashi, Tomoaki Fujioka, Fujioka, Tomoaki, Minami, Hironobu, Yamaguchi, Yoshiyuki, Takuya Tsunoda, Okusaka, Takuji, Hiroki Yamaue, Kiyotaka Okuno   +29 more
core   +1 more source

In Vivo Treatment with Insulin-like Growth Factor 1 Reduces CCR5 Expression on Vaccine-Induced Activated CD4⁺ T-Cells

Vaccines, 2023
At the heart of the DNA/ALVAC/gp120/alum vaccine’s efficacy in the absence of neutralizing antibodies is a delicate balance of pro- and anti-inflammatory immune responses that effectively decreases the risk of SIVmac251 acquisition in macaques.
Massimiliano Bissa, Veronica Galli, Luca Schifanella, Monica Vaccari, Mohammad Arif Rahman, Giacomo Gorini, Nicolò Binello, Sarkis Sarkis, Anna Gutowska, Isabela Silva de Castro, Melvin N. Doster, Ramona Moles, Guido Ferrari, Xiaoying Shen, Georgia D. Tomaras, David C. Montefiori, Kombo F. N’guessan, Dominic Paquin-Proulx, Pamela A. Kozlowski, David J. Venzon, Hyoyoung Choo-Wosoba, Matthew W. Breed, Joshua Kramer, Genoveffa Franchini   +23 more
doaj   +1 more source

mRNA booster vaccination protects aged mice against the SARS-CoV-2 Omicron variant

Communications Biology, 2022
A longitudinal study in mice reveals that a booster dose of mRNA vaccine BNT162b2 enhances humoral and cell-mediated responses and provides sterilizing immunity against Omicron-induced lung infection in aged animals.
Etsuro Nanishi, Marisa E. McGrath, Timothy R. O’Meara, Soumik Barman, Jingyou Yu, Huahua Wan, Carly A. Dillen, Manisha Menon, Hyuk-Soo Seo, Kijun Song, Andrew Z. Xu, Luke Sebastian, Byron Brook, Anna-Nicole Bosco, Francesco Borriello, Robert K. Ernst, Dan H. Barouch, Sirano Dhe-Paganon, Ofer Levy, Matthew B. Frieman, David J. Dowling   +20 more
doaj   +1 more source

Immunogenic T cell epitopes of SARS-CoV-2 are recognized by circulating memory and naïve CD8 T cells of unexposed individuals

EBioMedicine, 2021
Background: Recent studies have provided evidence of T cell reactivity to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in significant numbers of non-infected individuals, which has been attributed to cross-reactive CD4 memory T cells from
Isaac Quiros-Fernandez, Mansour Poorebrahim, Elham Fakhr, Angel Cid-Arregui   +3 more
doaj   +1 more source

Carbohydrate fatty acid monosulphate: oil-in-water adjuvant enhances SARS-CoV-2 RBD nanoparticle-induced immunogenicity and protection in mice

npj Vaccines, 2023
Development of SARS-CoV-2 vaccines that protect vulnerable populations is a public health priority. Here, we took a systematic and iterative approach by testing several adjuvants and SARS-CoV-2 antigens to identify a combination that elicits antibodies ...
Etsuro Nanishi, Francesco Borriello, Hyuk-Soo Seo, Timothy R. O’Meara, Marisa E. McGrath, Yoshine Saito, Jing Chen, Joann Diray-Arce, Kijun Song, Andrew Z. Xu, Soumik Barman, Manisha Menon, Danica Dong, Timothy M. Caradonna, Jared Feldman, Blake M. Hauser, Aaron G. Schmidt, Lindsey R. Baden, Robert K. Ernst, Carly Dillen, Jingyou Yu, Aiquan Chang, Luuk Hilgers, Peter Paul Platenburg, Sirano Dhe-Paganon, Dan H. Barouch, Al Ozonoff, Ivan Zanoni, Matthew B. Frieman, David J. Dowling, Ofer Levy   +30 more
doaj   +1 more source

Aging, cancer, and cancer vaccines [PDF]

Immunity & Ageing, 2012
AbstractWorld population has experienced continuous growth since 1400 A.D. Current projections show a continued increase - but a steady decline in the population growth rate - with the number expected to reach between 8 and 10.5 billion people within 40 years.
MAZZOLA, PAOLO, Radhi, S, Mirandola, L, ANNONI, GIORGIO, Jenkins, M, Cobos, E, Chiriva Internati, M.   +6 more
openaire   +3 more sources